Announcements Trials

Browse Landscape

Phase

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1 Dermatologic 1

Conditions

Lung Neoplasms 2 Glioma 2 Carcinoma, Non-Small-Cell Lung 2 Urinary Bladder Neoplasms 1 Urethral Neoplasms 1 Ureteral Neoplasms 1 Sarcoma 1 Rhabdomyosarcoma 1 Pheochromocytoma 1 Paraganglioma 1 Papillary renal cell carcinoma, sporadic 1 Pancreatic Ductal Adenocarcinoma 1 Osteoradionecrosis 1 Mouth Neoplasms 1 Melanoma 1 Hereditary leiomyomatosis and renal cell cancer 1 Gliosarcoma 1 Fallopian Tube Mucinous Adenocarcinoma 1 Craniopharyngioma 1 Colorectal Neoplasms 1 Carcinoma, Renal Cell 1 Brain Neoplasms 1

Interventions

pembrolizumab 57 Nivolumab 50 Ipilimumab 31 Specimen Handling 23 Magnetic Resonance Spectroscopy 19 Cyclophosphamide 14 Biopsy 11 fludarabine 10 binimetinib 10 Opdualag 10 trametinib 9 relatlimab 9 Radiosurgery 9 CTLA-4 Antigen 9 dabrafenib 8 lifileucel 7 fludarabine phosphate 7 aldesleukin 7 encorafenib 6 Interleukin-2 6 cemiplimab 5 atezolizumab 5 Paclitaxel 5 Blood Specimen Collection 5 X-Rays 4 Taxes 4 Pemetrexed 4 Gemcitabine 4 Cisplatin 4 Carboplatin 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Melanoma × Contrast Media × 90 days × Clear all

NCT07492121 2026-03-25

GAPIMET

University of Zurich

Phase 2 Not yet recruiting

DermatologicThoracic

Lung Neoplasms, Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡